Čájehuvvojit 1 - 6 oktiibuot 6 bohtosis ohcui Hansol Lee (15054787)', ohcanáigi: 0,01s Aiddostahte ozu
  1. 1
    Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

    Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1... Dahkki Hansol Lee (15054787)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

    Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1... Dahkki Hansol Lee (15054787)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

    Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1... Dahkki Hansol Lee (15054787)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

    Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1... Dahkki Hansol Lee (15054787)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

    Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain... Dahkki James S. Wilmott (15008931)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

    Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain M... Dahkki James S. Wilmott (15008931)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: